Friedrich-Baur Institute, Ludwig-Maximilian University - Munich
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schoser, Benedikt
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29
REACH, NCT05397470 / 2022-000389-16: Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Terminated
3
260
Europe, Canada, US
Losmapimod, Placebo oral tablet
Fulcrum Therapeutics
Facioscapulohumeral Muscular Dystrophy (FSHD)
11/24
11/24
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
104
Europe, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
EFES-BIO-SEP, NCT04767360: Effects of BIONESS in Rehabilitation of Stroke

Completed
N/A
32
Europe
Bioness-300
LMU Klinikum, Peter Young Neurological Clinic Medicalpark Bad Feilnbach, Germany
Stroke
10/21
12/22
NCT03458832: Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Recruiting
N/A
320
Europe, US
FSHD-specific functional rating scale, FSHD-COM, Electrical Impedance Myography, EIM
University of Kansas Medical Center, National Institute of Neurological Disorders and Stroke (NINDS), FSHD Society, Friends Research Institute, Inc., Muscular Dystrophy Association, AFM Telethon, University of Rochester, Leiden University Medical Center, Dyne Therapeutics
Facioscapulohumeral Muscular Dystrophy
06/27
12/27
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Recruiting
N/A
700
Europe, Canada, US, RoW
Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles
Myotonic Dystrophy 1, DM1
10/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schoser, Benedikt
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29
REACH, NCT05397470 / 2022-000389-16: Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Terminated
3
260
Europe, Canada, US
Losmapimod, Placebo oral tablet
Fulcrum Therapeutics
Facioscapulohumeral Muscular Dystrophy (FSHD)
11/24
11/24
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
104
Europe, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
EFES-BIO-SEP, NCT04767360: Effects of BIONESS in Rehabilitation of Stroke

Completed
N/A
32
Europe
Bioness-300
LMU Klinikum, Peter Young Neurological Clinic Medicalpark Bad Feilnbach, Germany
Stroke
10/21
12/22
NCT03458832: Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Recruiting
N/A
320
Europe, US
FSHD-specific functional rating scale, FSHD-COM, Electrical Impedance Myography, EIM
University of Kansas Medical Center, National Institute of Neurological Disorders and Stroke (NINDS), FSHD Society, Friends Research Institute, Inc., Muscular Dystrophy Association, AFM Telethon, University of Rochester, Leiden University Medical Center, Dyne Therapeutics
Facioscapulohumeral Muscular Dystrophy
06/27
12/27
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Recruiting
N/A
700
Europe, Canada, US, RoW
Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles
Myotonic Dystrophy 1, DM1
10/26
12/26

Download Options